- Report
- April 2025
- 175 Pages
Global
From €3975EUR$4,490USD£3,443GBP
- Report
- April 2025
- 175 Pages
Global
From €3975EUR$4,490USD£3,443GBP
- Report
- February 2024
- 288 Pages
Global
From €7038EUR$7,950USD£6,096GBP
Novoseven is a brand of hematological drugs used to treat and prevent bleeding episodes in patients with hemophilia and other bleeding disorders. It is a recombinant form of Factor VIIa, a clotting factor that is naturally produced in the body. Novoseven is used to treat and prevent bleeding episodes in patients with hemophilia A and B, von Willebrand disease, and other rare bleeding disorders. It is also used to treat and prevent bleeding episodes in patients undergoing surgery or other invasive procedures. Novoseven is administered intravenously or subcutaneously, depending on the patient's condition.
The Novoseven market is highly competitive, with several companies offering similar products. These companies include Novo Nordisk, Pfizer, Bayer, Biogen, and Shire. Show Less Read more